试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-11-29
Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer
编号:NCT00428194登记状态:入组前撤回企业 / 申办者:Masonic Cancer Center, University of Minnesota
药物 / 成分:cisplatin、erlotinib hydrochloride、radiation therapy
登记的停止原因(原文):Withdrawn due to lack of accrual
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-11-29
Safety and Tolerability of Varenicline in Schizophrenia (SATOVA)
编号:NCT00702793登记状态:入组前撤回企业 / 申办者:University of British Columbia
药物 / 成分:Varenicline
登记的停止原因(原文):No participants enrolled
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-11-29
NOrepinephrine and VasoprEssin Versus Norepinephrine aLone in Critically Ill Patients With Septic Shock
编号:NCT02454348登记状态:入组前撤回企业 / 申办者:University of Arkansas
药物 / 成分:Vasopressin、Norepinephrine
登记的停止原因(原文):PI left
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-11-29
Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus
编号:NCT02950688登记状态:入组前撤回企业 / 申办者:National Institute of Allergy and Infectious Diseases (NIAID)
药物 / 成分:Seasonal LAIV、Placebo、Wild-type A/California/2009-like Influenza Virus
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-11-29
A Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of GSK2894512 in Healthy Adult Subjects
编号:NCT03201978登记状态:入组前撤回企业 / 申办者:GlaxoSmithKline
药物 / 成分:GSK2894512 1% CREAM、GSK2894512 MATCHING VEHICLE CREAM
登记的停止原因(原文):The whole project was discontinued within GSK, hence this study was cancelled before enrolment.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-11-28
Vaginal DHEA for Women After Breast Cancer
编号:NCT01724242登记状态:入组前撤回企业 / 申办者:Hadassah Medical Organization
药物 / 成分:Vaginal DHEA、Placebo
登记的停止原因(原文):Inability to recruit patients
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-11-27
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus
编号:NCT02920424登记状态:入组前撤回企业 / 申办者:Janssen Research & Development, LLC
药物 / 成分:JNJ-56022473、Placebo
登记的停止原因(原文):The decision is based on a change in the benefit risk assessment of this drug for the lupus population targeted in this study.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-11-27
EGESTA - Emergent GI Therapy for Severe, Complicated CDI Using Fecal Microbiota Transplant
编号:NCT02968511登记状态:入组前撤回企业 / 申办者:Milton S. Hershey Medical Center
药物 / 成分:fecal microbiota transplant
登记的停止原因(原文):Lack of eligible patients
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-11-24
A Vaccine Study for High Risk Cancers
编号:NCT00944580登记状态:入组前撤回企业 / 申办者:Penn State University
药物 / 成分:MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine
登记的停止原因(原文):unexpectedly low screening results leading to poor accrual
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-11-24
Autologous Adipose-Derived Stromal Cells Delivered Into the Corpus Cavernous in Patients With Erectile Dysfunction
编号:NCT02087397登记状态:入组前撤回企业 / 申办者:Ageless Regenerative Institute
药物 / 成分:Liposuction、AD-SVF Cell Injection
登记的停止原因(原文):company dissolved
查看官方原始记录 ↗